Nazca acquires a majority shareholding in Diater
Through Nazca Fund IV, Nazca Capital has purchased the shareholding of Laboratorios Ferrer in Diater, a pioneering Spanish biopharmaceutical company in the sector of immunotherapy treatment of allergies. The founders, Dr Ricardo Palacios (president) and José Ángel López (CEO) participated in the operation, reinvesting all their shares in Diater.
Founded in 1999, Diater is specialised in the manufacture of products for diagnostic and immunotherapy treatment for allergic conditions, and has an extensive and innovative catalogue of products. Diater is a pioneer in the development of new products for both diagnosis and treatment, being notable for the quality, safety and effectiveness of its products. With over 55,000 patients treated per year, Diater is one of the leading companies in Spain and a point of reference at an international level.
In this new stage, Nazca, along with the management team of Diater, will stimulate the growth of the company, committing to the development and innovation of new diagnostic and treatment products, and entering new segments both nationally and internationally (over 20% of its sales are international). To do so, there are investments planned to increase the current capacity of Diater, improve its production facilities, and stockpile the main raw materials. Diater plans to acquire companies which complement its range of products.
The evolution of the company in recent years has been very positive, achieving sales of 17 million euros in 2018 and an EBITDA of 5 million euros, entailing annual growth of 14% and 50% in 2015 and 2018, respectively. In 2019, the company continues to show solid growth on the national and international market, and is forecast to end the year with sales of around 20 million euros.
DIATER has headquarters in Leganés (Madrid), 110 employees, and over 8,000m2 of modern production facilities on two floors in Madrid, where it produces and distributes to both the national and international market.
WindCorp Translink, PWC and Herbert Smith advised NAZCA and Deloitte advised the sellers.